OncoCyte Corp (OCX) Short Interest Update

OncoCyte Corp (NYSEAMERICAN:OCX) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,256,555 shares, a growth of 243.9% from the January 15th total of 365,397 shares. Based on an average trading volume of 4,949,763 shares, the days-to-cover ratio is currently 0.3 days. Currently, 6.8% of the company’s shares are sold short.

OncoCyte stock traded down $0.13 during midday trading on Monday, reaching $3.87. 636,396 shares of the stock traded hands, compared to its average volume of 2,368,775. OncoCyte has a 12-month low of $1.10 and a 12-month high of $6.92.

OncoCyte (NYSEAMERICAN:OCX) last announced its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02.



An institutional investor recently raised its position in OncoCyte stock. Vanguard Group Inc raised its stake in OncoCyte Corp (NYSEAMERICAN:OCX) by 3.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 410,275 shares of the biotechnology company’s stock after purchasing an additional 15,115 shares during the period. Vanguard Group Inc owned about 1.01% of OncoCyte worth $1,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of brokerages recently commented on OCX. Zacks Investment Research upgraded OncoCyte from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a report on Thursday, January 17th. began coverage on OncoCyte in a report on Monday, October 29th. They set a “positive” rating for the company. Lake Street Capital restated a “buy” rating on shares of OncoCyte in a report on Wednesday, December 19th. Finally, Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a report on Tuesday, January 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. OncoCyte currently has an average rating of “Buy” and a consensus price target of $5.33.

TRADEMARK VIOLATION NOTICE: This news story was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://dakotafinancialnews.com/2019/02/12/oncocyte-corp-ocx-short-interest-update.html.

OncoCyte Company Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Read More: Certificate of Deposit (CD)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply